The US FDA had said it would approve drugs based on China-only trials. Last month it did a U-turn, arguing that single-country trials are a step backward in achieving the racial diversity the US needs.

Sintilimab, made by Suzhou-based Innovent and US drugmaker Eli Lilly, has been developed and commercialised under a global agreement